



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gębicki *et al.*

Appl. No.: 10/585,892;

§ 371 Date: July 11, 2006

U.S. Nat'l Stage of PCT/EP05/50057;

I.A. Fd: January 7, 2005

For: Use of Quaternary Pyridinium Salts
as Vasoprotective Agents

Confirmation No.: 7625

Art Unit: 1614

Examiner: Nelson Clarence Blakely III

Atty. Docket: 2782.0010001/MAC

Amendment and Reply under 37 C.F.R. § 1.111

And Statement of Substance of Interview

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Mail Stop Amendment

Sir:

In reply to the Office action of April 14, 2009, please amend the application as follows:

Amendments to the **Specification** begin on page 3 of this paper.

Amendments to the **Claims** are reflected in the listing of claims that begins on page 8 of this paper.

Amendments to the **Abstract** begin on page 14 of this paper and include the attached sheet entitled "Abstract."

Amendments to the **Drawings** begin on page 15 of this paper and include attached replacement sheets for Figures 1, 9 and 10, and annotate sheets showing changes for Figures 9 and 10.

Remarks, arguments and the Statement of Substance of Interview begin on page 16 of this paper.

An **Appendix** including annotated and replacement drawing figures, and the Abstract of the Invention page, is attached following the final page, the signature page, of this paper.